Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

被引：16

作者：

Scagliotti, Giorgio

Purvish, Parikh

von Pawel, Joachim

Biesma, Bonna

Vansteenkiste, Johan

Manegold, Christian

Simms, Lorinda

Posther, Sugarman Katherine

Obasaju, Coleman

Blatter, Johannes

机构：

[1] Univ Turin, S Luigi Hosp, Orbassano, Italy

[2] Tata Mem Hosp, Bombay, Maharashtra, India

[3] Asklepios Fachklin Munchen, Munich, Germany

[4] Jeroen Bosch Ziekenhuis, sHertogenbosch, Netherlands

[5] Univ Hosp Gasthuisberg, Louvain, Belgium

[6] Heidelberg Univ, Med Ctr, Mannheim, Germany

[7] Eli Lilly Canada, Toronto, ON, Canada

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] Eli Lilly, Bad Homburg, Germany

来源：

关键词：

D O I：

10.1097/01.JTO.0000283088.78970.9b

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S306 / S306

页数：1